IP Library Granted Patent US 11,565,045
Granted Patent B2
US 11,565,045 · App. 16/811,765 · Granted Jan 31, 2023

System and method for adjusting insulin delivery

Inventors: Bryan Mazlish (Palo Alto, CA); Lane Desborough (Thousand Oaks, CA); Ross Naylor (Fullerton, CA)
Assignee: Bigfoot Biomedical, Inc.
A61M5/1723A61B5/14532A61B5/4839A61M5/14248A61M5/31568G16H20/17G16H40/63A61K38/28A61M5/003A61M2205/3379A61M2205/35A61M2205/3569A61M2205/3584A61M2205/502A61M2205/52A61M2205/8206A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,565,045
App. No.
16/811,765
Granted
Jan 31, 2023
Kind
B2
Abstract

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include adjusting user specific dosage parameters in response to one or more back-filled time segments associated with a diurnal time block.

Claims (39)

1. A method comprising:

receiving a total daily basal dose input;

determining, responsive to a first log-linear model representing a relationship between total daily basal dose and insulin sensitivity factor, an insulin sensitivity factor corresponding to the total daily basal dose input;

determining, responsive to a second log-linear model representing a relationship between total daily basal dose and carbohydrate-to-insulin ratio, a carbohydrate-to-insulin ratio corresponding to the total daily basal dose input; and

generating, at least partially responsive to determination of insulin sensitivity factor or determination of carbohydrate-to-insulin ratio, one or more of: an alert about one or more therapeutic parameters for controlling delivery of insulin to the body or a recommendation about the one or more therapeutic parameters for controlling delivery of inulin to the body.

2. The method of claim 1 , wherein the first log-linear model representing the relationship between total daily basal dose and insulin sensitivity factor and the second log-linear model representing the relationship between total daily basal dose and carbohydrate-to-insulin ratio represent relationships observed for a general population.

3. The method of claim 1 , wherein the first log-linear model representing the relationship between total daily basal dose and insulin sensitivity factor and the second log-linear model representing the relationship between total daily basal dose and carbohydrate-to-insulin ratio represent relationships observed for a given user.

4. The method of claim 1 , wherein receiving a total daily basal dose input comprises receiving a user-provided total daily basal dose input.

5. The method of claim 1 , wherein receiving a total daily basal dose input comprises receiving a system-adjusted total daily basal dose input.

6. The method of claim 5 , further comprising determining the system-adjusted total daily basal dose input by adjusting a user-provided total daily basal dose input responsive to a personalization factor.

7. The method of claim 1 , further comprising:

receiving an additional input comprising one or more of a user-specified insulin sensitivity factor input and a user-specified carbohydrate-to-insulin ratio input;

determining a first distance between the total daily basal dose input and either a distribution of the first log-linear model or a distribution of the second log-linear model; and

determining a second distance between the additional input and either the distribution of the first log-linear model or the distribution of the second log-linear model.

8. The method of claim 7 , further comprising, generating an alert responsive to observing that the first distance and the second distance exceed a threshold for differing from therapeutic values correlating to a general population.

9. The method of claim 8 , further comprising, providing a recommendation comprising an adjusted value for the total daily basal dose input, the additional input, or a combination thereof.

10. A system comprising:

an insulin delivery mechanism; and

a first controller configured to generate control signals for controlling delivery of insulin by the insulin delivery mechanism, the first controller configured to:

receive a total daily basal dose input;

determine, responsive to a first log-linear model representing a relationship between total daily basal dose and insulin sensitivity factor or a second log-linear model representing a relationship between total daily basal dose and carbohydrate-to-insulin ratio, at least one of an insulin sensitivity factor or a carbohydrate-to-insulin ratio corresponding to the total daily basal dose; and

generate, at least partially responsive to determination of insulin sensitivity factor or determination of carbohydrate-to-insulin ratio, one or more of: an alert about one or more therapeutic parameters for controlling delivery of inulin to the body or a recommendation about the one or more therapeutic parameters for controlling delivery of inulin to the body.

11. The system of claim 10 , wherein the first log-linear model representing the relationship between total daily basal dose and insulin sensitivity factor and the second log-linear model representing the relationship between total daily basal dose and carbohydrate-to-insulin ratio represent relationships observed for a general population.

12. The system of claim 11 , wherein the first controller comprises a mobile computing device.

13. The system of claim 11 , further comprising an insulin delivery device comprising:

the insulin delivery mechanism; and

a second controller, wherein the first controller comprises a mobile computing device in wireless communication with the second controller of the insulin delivery device.

14. The system of claim 11 , further comprising an insulin deliver device comprising the insulin delivery mechanism and the first controller.

15. The system of claim 10 , wherein the first log-linear model representing the relationship between total daily basal dose and insulin sensitivity factor and the second log-linear model representing the relationship between total daily basal dose and carbohydrate-to-insulin ratio represent relationships observed for a given user.

16. The system of claim 10 , wherein the first controller is further configured to, responsive to one or more of the total daily basal dose input, the determined insulin sensitivity factor, or the determined carbohydrate-to-insulin ratio, determine a insulin delivery profile.

17. The system of claim 16 , wherein the first controller is further configured to cause the insulin delivery mechanism to deliver insulin according to the insulin delivery profile.

18. The system of claim 17 , wherein receiving a total daily basal dose input comprises receiving a user provided total daily basal dose input.

19. The system of claim 17 , wherein receiving a total daily basal dose input comprises receiving a system-adjusted total daily basal dose input.

20. The system of claim 19 , wherein the first controller is further configured to determine the system-adjusted total daily basal dose input by adjusting a user-provided total daily basal dose input responsive to a personalizing factor.

21. A controller for controlling blood glucose levels by delivering insulin, the controller configured to:

receive a total daily basal dose input;

determine, responsive to a first log-linear model representing a relationship between total daily basal dose and insulin sensitivity factor observed for a general population, an initial insulin sensitivity factor corresponding to the total daily basal dose input;

determine, responsive to a second log-linear model representing a relationship between total daily basal dose and carbohydrate-to-insulin ratio observed for a general population, an initial carbohydrate-to-insulin ratio specific to the total daily basal dose input; and

generate, at least partially responsive to determination of insulin sensitivity factor or determination of carbohydrate-to-insulin ratio, one or more of: an alert about one or more therapeutic parameters for controlling delivery of inulin to the body or a recommendation about the one or more therapeutic parameters for controlling delivery of inulin to the body.

Assignments (16)
SECURITY INTEREST Recorded Jan 10, 2025
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069870/0519 →
SECURITY INTEREST Recorded Jan 10, 2025
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069870/0456 →
SECURITY INTEREST Recorded Sep 30, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069074/0001 →
SECURITY INTEREST Recorded Sep 30, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069073/0912 →
SECURITY INTEREST Recorded Sep 24, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069030/0104 →
SECURITY INTEREST Recorded Sep 24, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069030/0296 →
SECURITY INTEREST Recorded Sep 23, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069019/0142 →
SECURITY INTEREST Recorded Sep 23, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069019/0188 →
SECURITY INTEREST Recorded Sep 12, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 068948/0172 →
SECURITY INTEREST Recorded Sep 12, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 068948/0324 →
SECURITY AGREEMENT SUPPLEMENT Recorded Sep 7, 2023
From: INSULET CORPORATION
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 064840/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2023
From: BIGFOOT BIOMEDICAL, INC.
To: INSULET CORPORATION
Reel/Frame 062900/0001 →
RELEASE OF SECURITY INTEREST Recorded Feb 17, 2023
From: MADRYN FUND ADMINISTRATION, LLC
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 062793/0316 →
SECURITY INTEREST Recorded Feb 10, 2023
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 062702/0145 →
SECURITY INTEREST Recorded Mar 12, 2021
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 055583/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2020
From: MAZLISH, BRYAN; DESBOROUGH, LANE; NAYLOR, ROSS
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 052041/0733 →
Continuity (2)
Continuation 15870674 · Jan 12, 2018
Related Publication 20200197608A1 · Jun 25, 2020
Cited By (3)
US 12,318,577 US 12,485,223 US 12,551,621